查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1469148

表觀遺傳市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品和服務、技術、最終用戶、地區和競爭細分，2019-2029F

Epigenetic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Technology, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球表觀遺傳學市場價值為17.5 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為8.05%。醫療的重要領域，正在經歷顯著的成長和轉型。表觀遺傳學是在不改變 DNA 序列的情況下研究基因表現的遺傳變化，在各種生物過程和疾病進展中發揮關鍵作用。該市場涵蓋與表觀遺傳學研究和應用相關的技術、療法和服務，重塑醫療保健和生物醫學研究格局。

推動表觀遺傳市場的主要驅動力是癌症發生率的增加。表觀遺傳改變在癌細胞中普遍存在，有助於腫瘤發生和疾病進展。研究人員和臨床醫生利用表觀遺傳分析來識別與各種癌症類型相關的特定修飾，從而能夠開發針對個別患者表觀遺傳特徵的標靶治療。隨著全球癌症負擔的增加，對精準表觀遺傳學治療的需求持續成長，推動市場擴張。新一代定序和 DNA 甲基化分析等技術創新使科學家能夠準確、大規模地探索表觀遺傳修飾。將這些技術整合到研究和診斷工作流程中可以加速生物標記、治療標靶和診斷工具的發現，從而推動市場向前發展。

表觀遺傳學研究經費的增加是另一個重要的促進因素。政府、私人和學術資金支持專注於表觀遺傳療法的大型計畫、合作研究和臨床試驗。這些投資促進了突破性的發現和創新，將研究成果轉化為臨床應用並推動市場成長。老化與導致年齡相關疾病的複雜表觀遺傳變化有關。了解這些修飾對於制定干涉措施以減輕疾病風險、推動市場對解決與年齡相關的表觀遺傳學改變的技術和療法的需求至關重要。

對個人化醫療的需求促進了表觀遺傳分析在臨床實踐中的採用。表觀遺傳生物標記提供了對疾病易感性、預後和治療反應的見解，從而能夠根據個別患者的表觀遺傳特徵進行客製化治療。這種個人化醫療的趨勢促進了創新診斷分析和療法的發展，擴大了表觀遺傳學市場。變革。表觀遺傳學研究和介入有望徹底改變疾病診斷、治療和患者結果，將市場定位為推進醫療保健和個人化醫療的關鍵驅動力。

主要市場促進因素

表觀遺傳學資金不斷增加

個性化醫療需求

主要市場挑戰

表觀遺傳調控的複雜性

表觀遺傳學檢測的標準化

道德和法律考慮

對表觀遺傳機制的了解有限

主要市場趨勢

標靶表觀遺傳療法

表觀基因組生物標記的發現

表觀遺傳學在藥物開發中的整合

表觀遺傳學診斷的興起

細分市場洞察

技術洞察

產品服務洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球表觀遺傳學市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依產品服務（試劑盒試劑、酵素、儀器配件、軟體、服務）
    • 依技術（DNA 甲基化、組蛋白甲基化、其他）
    • 按最終用戶（學術和研究機構、製藥公司和生物技術公司、合約研究組織等）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按地區

第 5 章：亞太地區表觀遺傳學市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲表觀遺傳市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美表觀遺傳學市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲表觀遺傳學市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲表觀遺傳市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品服務
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球表觀遺傳市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Abcam Limited
  • Active Motif Inc
  • Hologic, Inc.
  • F Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • Element Biosciences
  • Dovetail Genomics LLC

第 15 章：策略建議

第 16 章：關於我們免責聲明

簡介目錄
Product Code: 22713

Global Epigenetic Marketwas valued at USD 1.75 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.05% through 2029.The Epigenetic Market, a crucial sector within genomics and personalized medicine, is experiencing remarkable growth and transformation. Epigenetics, the study of heritable changes in gene expression without altering the DNA sequence, plays a pivotal role in various biological processes and disease progression. This market encompasses technologies, therapies, and services related to epigenetic research and applications, reshaping healthcare and biomedical research landscapes.

A primary driver fueling the epigenetic market is the increasing incidence of cancer. Epigenetic alterations are prevalent in cancer cells, contributing to tumorigenesis and disease advancement. Researchers and clinicians utilize epigenetic profiling to identify specific modifications associated with various cancer types, enabling the development of targeted therapies tailored to individual patients' epigenetic signatures. With the global cancer burden rising, the demand for precise epigenetic treatments continues to grow, driving market expansion.Advancements in epigenetic research have significantly contributed to market growth. Innovations in technologies like next-generation sequencing and DNA methylation analysis enable scientists to explore epigenetic modifications accurately and at scale. Integration of these technologies into research and diagnostic workflows accelerates discovery of biomarkers, therapeutic targets, and diagnostic tools, propelling the market forward.

Increased funding for epigenetics research is another significant driver. Government, private, and academic funding supports large-scale projects, collaborative research, and clinical trials focused on epigenetic therapies. These investments foster groundbreaking discoveries and innovation, translating research findings into clinical applications and driving market growth.The rising geriatric population also drives the epigenetic market. Aging is associated with complex epigenetic changes contributing to age-related diseases. Understanding these modifications is crucial for developing interventions to mitigate disease risks, driving market demand for technologies and therapies addressing age-related epigenetic alterations.

The demand for personalized medicine boosts epigenetic profiling adoption in clinical practice. Epigenetic biomarkers offer insights into disease susceptibility, prognosis, and treatment response, enabling tailored treatments based on individual patients' epigenetic profiles. This trend toward personalized medicine fosters development of innovative diagnostic assays and therapies, augmenting the epigenetic market.The Epigenetic Market is undergoing transformative changes driven by technological advancements, increased research funding, and focus on personalized medicine. Epigenetic research and interventions hold promise for revolutionizing disease diagnosis, treatment, and patient outcomes, positioning the market as a key driver in advancing healthcare and personalized medicine.

Key Market Drivers

Growing funding for epigenetics

Increased funding for epigenetics research serves as a significant catalyst for driving growth in the epigenetic market. With greater financial support from governments, private organizations, and research institutions, scientists can conduct innovative studies to explore the intricacies of epigenetic regulation more comprehensively. These investments enable the development of advanced technologies, therapies, and diagnostic tools within the market. With substantial funding, researchers can delve into new epigenetic targets, expedite drug discovery processes, and enhance approaches to personalized medicine. Besides, financial backing encourages collaborative endeavors, facilitating the translation of research findings into practical applications. The availability of resources enhances research capabilities, thereby promoting market expansion and fostering breakthroughs in understanding and leveraging epigenetic mechanisms for diverse clinical and therapeutic purposes.

Demand for personalized medicine

The rising demand for personalized medicine is a significant driver of growth in the epigenetic market. Epigenetic modifications play a crucial role in tailoring treatment strategies to individual patients. With personalized medicine gaining traction, there is an increasing emphasis on understanding the unique epigenetic profiles of patients. Epigenetic profiling provides valuable insights into factors such as disease susceptibility, treatment response, and prognosis. By integrating this information with genomic and clinical data, healthcare providers can develop customized therapeutic interventions. Pharmaceutical companies are making substantial investments in epigenetic research to create targeted therapies that address patients' specific epigenetic profiles, leading to treatments that are both more effective and safer. As personalized medicine continues to gain prominence in healthcare, the epigenetic market experiences growing demand for its technologies and services, driving innovation and market expansion.

Key Market Challenges

Complexity of epigenetic regulation

The complexity of epigenetic regulation poses a significant challenge for the epigenetic market. Epigenetic mechanisms involve intricate processes such as DNA methylation, histone modifications, and non-coding RNA interactions, creating a multifaceted regulatory network. Understanding these complexities is essential for developing targeted therapies and diagnostic tools. However, deciphering the diverse interactions and their downstream effects on gene expression is a daunting task. Standardizing assays and interpreting epigenetic data accurately remain challenging due to the intricate nature of epigenetic regulation. Overcoming these complexities requires continuous research, innovative technologies, and multidisciplinary collaborations, ensuring reliable and reproducible results in epigenetic studies and applications, thereby advancing the epigenetic market.

Standardization of epigenetic assays

Standardization of epigenetic assays presents a significant challenge for the epigenetic market. Epigenetic research methods vary across laboratories and platforms, leading to inconsistencies in results. Differences in protocols, reagents, and data analysis hinder data comparability and reproducibility. Achieving uniformity is essential for reliable diagnostics and effective treatments. Developing standardized assays that ensure accurate, consistent, and reproducible outcomes is crucial. Overcoming this challenge requires collaborative efforts between researchers, industry experts, and regulatory bodies to establish common protocols and guidelines. Standardization efforts are vital to advancing the field, enhancing the reliability of epigenetic data, and fostering trust in epigenetic technologies, consequently driving the epigenetic market forward.

Ethical and legal considerations

Ethical and legal considerations pose a substantial challenge for the epigenetic market. Epigenetic research raises concerns about consent, privacy, and the potential misuse of genetic information. Ethical dilemmas arise regarding the disclosure of epigenetic data, especially in the context of predictive and personalized medicine. Legal frameworks often struggle to keep pace with the rapid advancements in epigenetic technologies, leading to ambiguities in regulations and patents. Addressing these challenges requires robust ethical guidelines, clear legislation, and transparent communication between stakeholders. Striking a balance between scientific progress, patient rights, and ethical principles is crucial for fostering public trust and ensuring the responsible growth of the epigenetic market.

Limited understanding of epigenetic mechanisms

The limited understanding of epigenetic mechanisms poses a formidable challenge for the epigenetic market. Despite significant progress, numerous aspects of epigenetic regulation remain elusive. Gaps in knowledge about specific modifications, their interactions, and their role in diseases hinder the development of targeted therapies and precise diagnostic tools. This lack of comprehensive understanding complicates research efforts, leading to uncertainties in therapeutic outcomes and diagnostic accuracy. Bridging these gaps requires extensive research, interdisciplinary collaborations, and innovative technologies. Advancements in genomics, epigenomics, and computational biology are crucial to unravel the complexities, enabling a deeper understanding of epigenetic mechanisms and driving the development of effective and reliable solutions within the epigenetic market.

Key Market Trends

Targeted epigenetic therapies

Targeted epigenetic therapies have emerged as a prominent trend in the epigenetic market. Unlike conventional treatments, these therapies focus on modifying specific epigenetic marks associated with diseases, enabling precise interventions. Advancements in epigenetic research have led to the development of drugs targeting enzymes and proteins involved in epigenetic regulation. These therapies hold immense potential for various conditions, including cancer, where aberrant epigenetic modifications play a significant role. By modulating gene expression patterns, targeted epigenetic therapies offer personalized and more effective treatment options. Pharmaceutical companies invest in research and development, driving innovation in this field, thereby reshaping the landscape of disease management and contributing to the growth of the epigenetic market.

Epigenomic biomarker discovery

Epigenomic biomarker discovery stands as a pivotal trend in the epigenetic market. Researchers are increasingly focusing on identifying specific epigenetic modifications associated with diseases, paving the way for precise diagnostics and targeted therapies. These biomarkers offer valuable insights into disease risk, progression, and treatment response. Advanced technologies, such as high-throughput sequencing and bioinformatics, empower scientists to analyze vast epigenomic datasets, accelerating biomarker discovery. Pharmaceutical companies and diagnostic firms are investing in these endeavors, driving innovation and the development of diagnostic assays. Epigenomic biomarkers not only enhance disease detection but also enable personalized treatment strategies, making them a cornerstone in the evolving landscape of healthcare and fueling the growth of the epigenetic market.

Integration of epigenetics in drug development

The integration of epigenetics in drug development has emerged as a transformative trend in the epigenetic market. Pharmaceutical companies are increasingly incorporating epigenetic research into their drug discovery processes. By understanding the role of epigenetic modifications in diseases, researchers can design targeted therapies, leading to more effective and safer treatments. Epigenetic insights enable the identification of novel drug targets and the development of precision medicines tailored to specific patient profiles. This trend fosters collaborations between academia and industry, driving innovation and accelerating the development of epigenetic drugs. The integration of epigenetics in drug development signifies a paradigm shift, offering promising avenues for personalized therapies and reshaping the future of medicine, thus propelling the epigenetic market forward.

Rise in epigenetic diagnostics

The rise in epigenetic diagnostics represents a significant trend in the epigenetic market. Advances in epigenomic profiling techniques enable the identification of unique epigenetic signatures associated with diseases, revolutionizing diagnostic approaches. Epigenetic biomarkers provide precise disease insights, aiding in early detection, prognosis, and treatment selection. These non-invasive, highly specific tests offer a deeper understanding of patients' conditions, allowing for personalized treatment strategies. Pharmaceutical companies and diagnostic laboratories invest in research and development, driving the commercialization of epigenetic diagnostic assays. The increasing adoption of epigenetic diagnostics signifies a paradigm shift towards more accurate, tailored healthcare solutions, fueling market growth and enhancing patient outcomes within the epigenetic market.

Segmental Insights

Technology Insights

Basedon the Technology, DNA methylation dominates the epigenetic market due to its pivotal role in regulating gene expression. Aberrant DNA methylation patterns are associated with various diseases, making them valuable diagnostic and therapeutic targets. Research focusing on understanding and manipulating DNA methylation marks has led to the development of innovative therapies and diagnostic tools. DNA methylation-based assays provide crucial insights into disease mechanisms, allowing for early detection and personalized treatment strategies. The precision and reliability of DNA methylation analysis have made it a cornerstone in epigenetic research, driving investments, collaborations, and commercialization efforts. Its versatility and significance position DNA methylation as a dominant force shaping the future of the epigenetic market.

Product Service Insights

Kits and reagents dominate the epigenetic market due to their essential role in enabling precise and efficient epigenetic research. Researchers rely on specialized kits and reagents to perform various epigenetic assays, such as DNA methylation analysis and chromatin immunoprecipitation. These products provide standardized protocols, ensuring accuracy and reproducibility in experiments. As demand for epigenetic studies grows, pharmaceutical companies, research institutions, and diagnostic labs heavily invest in these user-friendly and cost-effective solutions. The availability of comprehensive kits and high-quality reagents streamlines the research process, making them indispensable tools in laboratories worldwide. Their convenience, reliability, and widespread use establish kits and reagents as the dominant driving force in the epigenetic market.

Regional Insights

North America asserts dominance in the epigenetic market owing to its advanced healthcare infrastructure, substantial research funding, and a robust biotechnology sector. The region houses prominent pharmaceutical and biotech companies actively engaged in epigenetic research and drug development. Leading research institutions and universities, coupled with strategic collaborations between academia and industry, drive innovation in epigenetic technologies. Secondarily, supportive government policies, well-defined regulatory frameworks, and a high prevalence of chronic diseases fuel the demand for epigenetic diagnostics and therapies. The availability of skilled professionals and cutting-edge research facilities further solidify North America's position as a hub for epigenetic advancements, propelling its dominance in the global epigenetic market.

Key Market Players

Abcam Limited

Active Motif Inc

Hologic, Inc.

F Hoffmann-La Roche Ltd.

Illumina, Inc.

Qiagen N.V.

Thermo Fisher Scientific Inc

Novartis AG

Element Biosciences

Dovetail Genomics LLC

Report Scope:

In this report, the Global Epigenetic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epigenetic Market,By Product Service:

  • Kits Reagents
  • Enzymes
  • Instruments Accessories
  • Software
  • Services

Epigenetic Market,By Technology:

  • DNA Methylation
  • Histone Methylation
  • Others

Epigenetic Market,By End user:

  • Academic and Research Institutes
  • Pharmaceutical Companies and Biotechnology Companies
  • Contract Research Organizations
  • Others

Epigenetic Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Epigenetic Market.

Available Customizations:

Global Epigenetic marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Epigenetic Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Product Service (Kits Reagents, Enzymes, Instruments Accessories, Software, Services)
    • 4.2.2.By Technology (DNA Methylation, Histone Methylation, Others)
    • 4.2.3.By End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations, Others)
    • 4.2.4.By Region
    • 4.2.5.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Product Service
    • 4.3.2.By Technology
    • 4.3.3.By End user
    • 4.3.4.By Region

5.Asia Pacific Epigenetic Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Product Service
    • 5.2.2.By Technology
    • 5.2.3.By End user
    • 5.2.4.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Epigenetic Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Product Service
        • 5.3.1.2.2.By Technology
        • 5.3.1.2.3.By End user
    • 5.3.2.India Epigenetic Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Product Service
        • 5.3.2.2.2.By Technology
        • 5.3.2.2.3.By End user
    • 5.3.3.Australia Epigenetic Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Product Service
        • 5.3.3.2.2.By Technology
        • 5.3.3.2.3.By End user
    • 5.3.4.Japan Epigenetic Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Product Service
        • 5.3.4.2.2.By Technology
        • 5.3.4.2.3.By End user
    • 5.3.5.South Korea Epigenetic Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Product Service
        • 5.3.5.2.2.By Technology
        • 5.3.5.2.3.By End user

6.Europe Epigenetic Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Product Service
    • 6.2.2.By Technology
    • 6.2.3.By End user
    • 6.2.4.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Epigenetic Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Product Service
        • 6.3.1.2.2.By Technology
        • 6.3.1.2.3.By End user
    • 6.3.2.Germany Epigenetic Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Product Service
        • 6.3.2.2.2.By Technology
        • 6.3.2.2.3.By End user
    • 6.3.3.Spain Epigenetic Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Product Service
        • 6.3.3.2.2.By Technology
        • 6.3.3.2.3.By End user
    • 6.3.4.Italy Epigenetic Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Product Service
        • 6.3.4.2.2.By Technology
        • 6.3.4.2.3.By End user
    • 6.3.5.United Kingdom Epigenetic Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Product Service
        • 6.3.5.2.2.By Technology
        • 6.3.5.2.3.By End user

7.North America Epigenetic Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Product Service
    • 7.2.2.By Technology
    • 7.2.3.By End user
    • 7.2.4.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Epigenetic Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Product Service
        • 7.3.1.2.2.By Technology
        • 7.3.1.2.3.By End user
    • 7.3.2.Mexico Epigenetic Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Product Service
        • 7.3.2.2.2.By Technology
        • 7.3.2.2.3.By End user
    • 7.3.3.Canada Epigenetic Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Product Service
        • 7.3.3.2.2.By Technology
        • 7.3.3.2.3.By End user

8.South America Epigenetic Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Product Service
    • 8.2.2.By Technology
    • 8.2.3.By End user
    • 8.2.4.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Epigenetic Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Product Service
        • 8.3.1.2.2.By Technology
        • 8.3.1.2.3.By End user
    • 8.3.2.Argentina Epigenetic Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Product Service
        • 8.3.2.2.2.By Technology
        • 8.3.2.2.3.By End user
    • 8.3.3.Colombia Epigenetic Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Product Service
        • 8.3.3.2.2.By Technology
        • 8.3.3.2.3.By End user

9.Middle East and Africa Epigenetic Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Product Service
    • 9.2.2.By Technology
    • 9.2.3.By End user
    • 9.2.4.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Epigenetic Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Product Service
        • 9.3.1.2.2.By Technology
        • 9.3.1.2.3.By End user
    • 9.3.2.Saudi Arabia Epigenetic Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Product Service
        • 9.3.2.2.2.By Technology
        • 9.3.2.2.3.By End user
    • 9.3.3.UAE Epigenetic Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Product Service
        • 9.3.3.2.2.By Technology
        • 9.3.3.2.3.By End user

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Epigenetic Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.Abcam Limited
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.4.Financials (In case of listed)
    • 14.1.5.Recent Developments
    • 14.1.6.SWOT Analysis
  • 14.2.Active Motif Inc
  • 14.3.Hologic, Inc.
  • 14.4.F Hoffmann-La Roche Ltd.
  • 14.5.Illumina, Inc.
  • 14.6.Qiagen N.V.
  • 14.7.Thermo Fisher Scientific Inc
  • 14.8.Novartis AG
  • 14.9.Element Biosciences
  • 14.10.Dovetail Genomics LLC

15.Strategic Recommendations

16.About Us Disclaimer